Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel
NASDAQ:AKTS

Aktis Oncology Q1 2026 Earnings Report

Aktis Oncology logo
$20.34 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$21.25 +0.91 (+4.47%)
As of 05/22/2026 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aktis Oncology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.37
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Aktis Oncology Revenue Results

Actual Revenue
$3.23 million
Expected Revenue
$2.23 million
Beat/Miss
Beat by +$997.00 thousand
YoY Revenue Growth
N/A

Aktis Oncology Announcement Details

Quarter
Q1 2026
Date
5/11/2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Aktis Oncology's Q2 2026 earnings is estimated for Wednesday, June 3, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Aktis Oncology's Q1 2026 Press ReleasePress Release
(8-K)
Aktis Oncology's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Aktis Oncology Earnings Headlines

A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound
May 25 at 5:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/look-aktis-oncology-akts-valuation-190538185.html
Aktis Oncology Inc.: Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue ...
May 22, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68571226-aktis-oncology-inc-aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limi-399.htm
You cannot escape this reality
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7 ...
May 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limited-normal-tissue-exposures-in-patients-with-b7-h3-expressing-tumors-1036185614
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting
May 21, 2026  |  quiverquant.comQ
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299806/0/en/aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limited-normal-tissue-exposures-in-patients-with-b7-h3-.html
See More Aktis Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aktis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aktis Oncology and other key companies, straight to your email.

About Aktis Oncology

Aktis Oncology (NASDAQ:AKTS) (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities.

As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy.

View Aktis Oncology Profile
Earnings Tools